寶光股份(600379.SH):控股股東合計增持公司12.47萬股股份
格隆匯10月7日丨寶光股份(600379.SH)公佈,2024年9月30日,公司收到控股股東寶光集團《關於增持寶光股份股票的通知》:寶光集團於2024年9月30日,通過集中競價交易方式合計增持公司124,700股股份,增持股份數達到公司總股本的0.0378%。增持後寶光集團持有公司99,060,484股股份,佔公司總股本的30%。
寶光集團的此次增持是基於對公司未來發展前景的信心和對公司長期投資價值的認可,同時參考政策環境、市場狀況、股價表現等因素,為提升投資者信心,根據自身經營情況綜合決策而採取的操作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.